PROSPECTIVE RANDOMIZED STUDY COMPARING THE EFFICACY OF BIOEQUIVALENT DOSES OF GLYCOSYLATED AND NONGLYCOSYLATED RG-CSF FOR MOBILIZING PERIPHERAL-BLOOD PROGENITOR CELLS

Thirty patients diagnosed with breast cancer were included in a prospe ctive randomized study comparing the in vivo priming effect of bioequi valent doses of glycosylated (lenograstim) and nonglycosylated (filgra stim) rG-CSF administration. Analysis of the efficacy of equivalent bi ological doses of both rG-CSFs showed no significant differences eithe r in the mobilization of the subpopulations of PBPC considered (CD34(), CD34(+)/38(-), CD34(+)/DR(-)), the content of such CD34(+) cell sub sets in the leukapheresis product, or the cost of the mobilization and collection procedures between both recombinant molecules. These resul ts suggest that priming with bioequivalent doses of the two commercial ly available forms of glycosylated or nonglycosylated rG-CSF has a sim ilar in vivo effect on PBPC mobilization.